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Abstract
BACKGROUND: Aldosterone plays a role in the initiation and development of heart failure (HF). During congestive 
HF, the initial reduction in cardiac output stimulates the renin-angiotensin-aldosterone system, which in turn exerts 
additional stress on the heart.
AIM: This research was aimed to explore the comparison of aldosterone levels between Class I-II functional HF and 
Class III-IV HF to optimize therapy in cases of HF.
METHODS: The study design is an observational study with a cross-sectional approach. This study was conducted 
at the Department of Internal Medicine Dr. Moh Hoesin Hospital in Palembang, Indonesia. All patients diagnosed 
with functional III-IV functional HF disease based on symptoms clinical, physical, and electrocardiography (ECG) 
examination and history of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blocker 
(ARB) treatment are willing to join the research by signing informed consent.
RESULTS: There is no confounding variable that has a significantly different effect on the group I-II and III-IV 
functional HF groups. Aldosterone levels also did not show a significant difference between the group New York 
Heart Association (NYHA) I-II active HF group and the NYHA Class III-IV functional HF group (p = 0.445).
CONCLUSION: Serum aldosterone levels in patients with Class I-II functional HF and those with Class III-IV 
functional HF who consumed ACEIs or ARBs were not significantly different.
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Introduction
The prevalence of heart failure (HF) in developed 
countries is around 1–2% of the entire population. 
The incidence increases with age, with an increase 
of 20/1000 individuals at the age of 65–69 years and 
more than 80/1000 individuals beyond 85 years old [1]. 
Patients with HF often require hospitalization because of 
worsening symptoms. More than 1 million patients are 
treated for HF each year. Reports show that the average 
rate of rehospitalization in the 1st month is around 25%, 
and the average rate of rehospitalization in 3 months 
and 1 year is 30 and 50% [1], [2], [3]. Pharmacological 
therapy is a significant component of HF management, 
which includes angiotensin-converting-enzyme 
inhibitors (ACEIs), angiotensin II-receptor blockers 
(ARB), β-blockers, digoxin, diuretics, and aldosterone 
antagonists. Hydralazine and nitrate can also be given 
in some cases. ACEIs and β blockers have become 
standard therapy in all patients with systolic HF, with 
aldosterone antagonists and hydralazines/nitrates, which 
are only recommended in individual patients [4], [5].
Aldosterone is a mineralocorticoid that is 
synthesized by the adrenal, cardiac, and vascular 
glands and provides pleiotropic effects on these 
organs. The role of aldosterone in the pathophysiology 
of cardiovascular disease has long been known. 
Aldosterone is a neurohormonal part of the renin-
angiotensin-aldosterone system (RAAS) component 
that is responsible for the regulation of blood pressure, 
peripheral resistance, fluid, and electrolyte regulation. 
Aldosterone also plays a role in the occurrence of 
heart muscle fibrosis directly through mineralocorticoid 
receptors. Increased synthesis of aldosterone is 
stimulated mainly by angiotensin II (AT2) through the 
angiotensin-1 (AT1) receptor in the adrenal gland 
glomerulus zone cells. It is also encouraged by the 
hormone adrenocorticotropic hormone, potassium ions 
(hyperkalemia), endothelin, prolactin, vasopressin, 
catecholamines, acetylcholine, prostaglandins, and 
nitric oxide [5]. In HF, aldosterone plays a role in 
the initiation and development of its disease. During 
congestive HF, the initial reduction in cardiac output 
stimulates neurohormonal compensatory systems, 
such as the sympathetic nervous system and RAAS, 
which in turn exerts additional stress on the heart 
muscle. From several studies found a decrease in AT2 
levels with ACEIs, ARBs, or a combination. Still, both 
are not enough to inhibit aldosterone production; this 
is known as “aldosterone escape.” A study showed 
that 24% of patients taking ACEIs had elevated 
serum aldosterone levels. The cause of a secondary 
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increase in plasma aldosterone levels in patients 
who have received ACE blockers is unclear, but it 
may be an “escape phenomenon” of ACE blockers. 
Alternative pathways from the formation of AT2 can 
encourage increased production of AT2 so that there 
remains an increase in aldosterone levels after the 
enzyme conversion is inhibited. The initial treatment 
strategy focuses on reducing AT2 by administering 
ACE inhibitors because it is suspected that ACEIs 
can suppress the production of AT2 and aldosterone. 
However, several studies have shown that ACEIs and 
AT1 blockers only temporarily reduce aldosterone 
levels. There are several hypotheses that an increase 
in aldosterone levels results from the non-ACE pathway 
and the activation of the ACE-2 [6], [7], [8], [9], [10].
There are no specific studies on the comparison 
of serum aldosterone levels in patients with Class 
I-II functional HF with Class III-IV functional HF who 
consume ACEIs/ARBs. This study seeks to explore the 
comparison of aldosterone levels between Class I-II 
functional HF and Class III-IV HF to optimize therapy 
in cases of HF.
Methods
The design of this study is a quantitative 
observational study with a cross-sectional approach. 
This study was conducted at the Department of Internal 
Medicine Dr. Moh Hoesin Hospital in Palembang, 
Indonesia, where the study sample was all patients 
with HF in the Department of Internal Medicine who 
met the inclusion and exclusion criteria. The inclusion 
criteria were all patients diagnosed with outpatient 
functional I-II functional HF based on clinical symptoms, 
physical examination, and electrocardiography (ECG), 
as well as the history of consuming ACEIs/ARB. All 
patients are willing to join the research by signing 
informed consent. Exclusion criteria are patients with 
chronic kidney failure, patients suffering from primary 
hyperaldosteronism or thyroid disease or liver disease, 
patients undergoing treatment with anti-aldosterone/
spironolactone, patients with myocardial infarction, and 
patients with chronic obstructive pulmonary disease 
and cor pulmonale.
A total of 32 subjects were included in this study 
using the consecutive sampling technique. Submission 
of subjects was conducted from December 1, 2019 to 
December 31, 2019. The ethics committee approved this 
study of the Faculty of Medicine of Universitas Sriwijaya 
with registration number 278/kptfkunsri-rsmh/2019.
The independent variable in this study is serum 
aldosterone levels, with the dependent variable being 
functional HF Class I-II and III-IV who consume ACEIs/
ARB. HF, according to the New York Heart Association 
(NYHA), a functional class is divided into four categories 
based on complaints of occurrence of shortness of 
breath. Class I, there were no complaints of shortness 
of breath even with substantial activities. Class II, if there 
are complaints of shortness of breath when doing rather 
strenuous activities such as climbing stairs or walking 
100 m. Class III, if there are complaints of shortness of 
breath when doing light activities or daily activities such as 
sweeping the house, bathing, and wearing clothes. Class 
IV, if there are complaints of tightness at rest or lying on their 
backs, the patient needs a pillow to raise his head. While 
confounding variables are body mass index (BMI), age, 
sex, hypertension, kidney disease, impaired liver function, 
hyperkalemia, hypernatremia, smoking, and dyslipidemia.
Data management and analysis are performed 
using the SPSS version 22.0 for Windows program. 
The results are described in the form of narratives, 
tabulations, diagrams, or pictures. Bivariate analysis 
was performed as a comparative analysis of serum 
aldosterone levels between Class I-II functional HF 
and Class II-IV functional HF using an unpaired t-test. 
Analysis to control for confounding variables uses a 
logistic regression test.
Results
Table 1 shows the baseline status and 
laboratory characteristics of the study subjects. The 
majority of subjects are male, age more than 55 years, 
the majority of high school and college-educated with 
the majority of labor and entrepreneurial work. The 
majority of participants smoke, with the etiology of 
most of the HF being due to hypertensive heart disease 
(HHD) and the prevalence of dyslipidemia and having 
a BMI of more than 24.9 kg/m2. The majority of the 
subjects’ blood pressure is also high.
Table 2 shows that there is no confounding 
variable that has a significantly different effect on the 
Group I-II and III-IV functional HF groups. Aldosterone 
levels also did not show a significant difference between 
the group NYHA I-II functional HF group and the NYHA 
Class III-IV functional HF group.
Discussion
ACEI drugs work by inhibiting the activity 
of ACE in converting AT1 to AT2 and inhibiting the 
degradation of bradykinin, with the result of reducing 
peripheral resistance and ultimately lowering blood 
pressure. In this study, aldosterone levels remained 
high in both groups despite the use of ACEIs or 
ARBs [11], [12], [13], [14], [15]. However, suppression 
of ANG-II production and serum aldosterone secretion 
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by ACEIs and ARBs cannot be sustained even with 
long-term treatment.
At the beginning of treatment, ACEIs or ARBs 
can indeed eliminate most Ang-II from the serum, but 
in long-term treatment, Ang-II levels will appear and be 
re-measured. This situation is called “Ang-II reactivation” 
and this is associated with a poor prognosis. This is due to 
ACEIs and ARBs unable to inhibit the production of Ang-II 
produced by other pathways, namely non-renin and non-
ACE lines. The continued formation of Ang-II means that it 
will also continue to stimulate aldosterone secretion. This 
phenomenon is considered as one of the fixed mechanisms 
of cardiovascular complications [16], [17], [18], [19], [20], [21], 
[22]. ACEIs are not able to suppress ACE activity and 
serum aldosterone secretion in the long term; this may 
be due to increased serum potassium levels. It has been 
explained that potassium levels previously, together 
with AT2 synergistically stimulate serum aldosterone 
production [23]. The above phenomena might occur in 
patient with Class I-II and Class III-IV functional HV who 
have consumed ACEIs or ARBs in this study. The use 
of ACE with ARB in the long term was unable to suppress 
Ang-II activity, and aldosterone secretion might be related 
to changes in the responsive mechanisms of various 
receptors involved with RAAS itself.
The results of this study are in line with a survey 
conducted by Kobayashi et al. in 2020, which stated that 
aldosterone did not play a role in clinical improvement 
of HF patients, improved therapeutic response, and had 
no effect on improving patient outcomes with HF [24]. 
This study is one of the researches that compared the 
aldosterone levels of patients with HF categories NYHA 
I-II and NYHA III-IV in an Asian population. The limitation 
of this study is the limited number of research samples.
Conclusion
Serum aldosterone levels in patients with 
Class I-II functional HF and those with Class III-IV 
functional HF who consumed ACEIs or ARBs were not 
significantly different.
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